SCHEMBL6096089

SCHEMBL6096089

CNS(=O)(=O)N1CCC(O)(c2ccc(Br)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
OPRM1 P35372 3/20 0.46
OPRK1 P41145 3/20 0.46
OPRD1 P41143 2/20 0.46
OPRL1 P41146 2/20 0.46
CCR1 P32246 4/20 0.46
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974153 0.83 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL578244 0.74 OPRM1 (0.55) CA12CA1CA2CA7CA9
SCHEMBL14282269 0.72 LMNA (0.62) CA12CA1CA2CA7CA9
SCHEMBL578234 0.72 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL16799100 0.72 CCR1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL16936710 0.71 OPRM1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL12526871 0.71 OPRM1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL15573716 0.71 OPRM1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL6095578 0.71 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL23901648 0.70 OPRL1 (0.63) OPRM1OPRK1OPRD1OPRL1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 US disclosed
US-6492367-B1 Sulfamato hydroxamic acid metalloprotease inhibitor G. D. SEARLE & COMPANY 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 CA12 214/4885CA1 65/4885CA2 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.